Table 2.

Summary of Cost-effectiveness Studies Comparing Anticoagulants with Aspirin

Study ID	Comparator #1	Aspirin regimen	Horizon	Major Bleeding rate (%) Anticoagulant / ASA	DVT rate (%) Anticoagulant rate / ASA	PE rate (%) Anticoagulant / ASA	Death Rate (%) Anticoagulant / ASA	Cost-Effectiveness Result Reported by Study Authors, converted to 2009 USD*
THR Results from Short Horizon Analysis
Sarasin 2002	Enoxaparin 40 mg qd × 10 days	300 mg qd × 10 days	90 days	0.49 / 0.48	5.59 / 8.79 ‡	1.12 / 1.76	ns /ns	LMWH ICER = $1300 / VTE avoided
Abdool-Carrim 1997	Enoxaparin 40 mg or Dalteparin 4,000-5,000 IUs qd × 28 days post-discharge	160 mg qd × 28 days post-discharge	ns	2.00 / 0.70	21.0 / 35.0 ‡	ns / ns	1.10 / 1.50	LMWH ICER = $7200 / VTE avoided
Sarasin 2002	Warfarin dose not specified × 28 days post-discharge	160 mg qd × 28 days post-discharge	90 days	0.59 / 0.48	6.52 / 8.79 ‡	1.30 / 1.76	ns /ns	Warfarin ICER = $1700 / VTE avoided

Abbreviations: LMWH = low molecular weight heparin, ns = not specified, VTE = venous thromboembolism, QALY = quality adjusted life-year

^*Cost-effectiveness result is the incremental cost-effectiveness ratio (ICER). To arrive at ICER values, incremental costs reported in foreign currencies were inflated or deflated according to readily available consumer price indices, converted to USD via 2005 World Health Organization purchasing price parity indices, and then inflated to 2009 USD using the Bureau of Labor Statistics consumer price calculator available at www.bls.gov.

^‡DVT rate not specified (i.e. clinical vs. radiographic and proximal vs distal)